Rezultati pretraživanja
  1. 11. ruj 2019.

    Our experts are looking forward to discussing with you new perspective on at the Weimar . Visit us at booth 29 -ADM®

  2. 17. sij

    is killing more people than cancer. Learn more about Adrenomed’s lead product candidate: a first-in-class antibody counteracting vascular leakage and shock to rescue in sepsis.

  3. 15. stu 2019.

    develops a new strategy against : tackle the disease heterogeneity through intervening downstream in the pathological process by targeting . Read more about the science behind it and the company’s mission in

  4. 12. stu 2019.

    Today, our CBO, Dr. Hein, will give a presentation at , 11:15 AM, Level 1/Hall B1/Room 6 🎤👩‍🏫. Join and discover how tackles by restoring with its first-in-class

  5. 17. ruj 2019.

    Thank you for joining our experts at in Weimar and for the shared knowledge around enhancing and going beyond standard of care.

  6. 4. stu 2019.

    In less than a week, will be heading off to to attend , 11-13.11.! Join the company presentation to learn about our program to rescue in ! See you there!

  7. 11. ruj 2019.

    Only one day until the . Join our symposium at the in on September 13: "Beyond Standard of Care – New Perspectives on Vascular Integrity in Shock” ®

  8. 26. ruj 2019.

    announces the successful completion of enrollment in the 300-patient PoC Phase II trial, AdrenOSS-2. “By restoring , we aim to provide physicians with a new therapy for patients,” said Dr. Andreas Bergmann, CSO

  9. 1. lis 2019.

    Today, Dr. Peter Pickkers will give a talk “ in , effect of the non-inhibitory antibody . This drug candidate developed by has a novel MoA to restore

  10. 24. svi 2019.

    Scientists at are studying whether a monoclonal antibody restoring is safe and has positive effects on organ functions of patients with .

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.